#InnovativeCollaboration
AnHorn Medicines, an AI-driven drug discovery company focused on protein degradation, has partnered with European startups to explore new treatment targets for prostate cancer.
On 20 February 2024, Anhorn Medicines announced its collaboration with Czech startup AI|ffinity, Swiss-based NexMR AG, and CEITEC - Central European Institute of Technology, facilitated by Taiwania Capital. Together, they will harness core AI technologies to discover innovative drugs targeting prostate cancer. This partnership marks a precedent for collaboration between Taiwanese #pharmaceutical companies, European #startups, and research institutions.

Dr. Chu-Chiang Lin (林助強), founder and CEO of Anhorn Medicines, highlighted the scientific potential of this collaboration, which aims to overcome current limitations in prostate cancer treatment and expand therapeutic options.

Read more: https://lnkd.in/evGEWMd7
Stay updated with #Globalbio for more groundbreaking R&D in #biomedicine!
#DrugDiscovery #TargetedProteinDegradation #NewTherapies #AI